Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

the overall percent weight loss in the EQUIP study was 11% for patients on full dose Qnexa, as compared to 1.6% for the placebo group."

Also included in the presentation were discontinuation rates for cognitive events. Overall, these rates were low and the events were generally mild to moderate and reversible with discontinuation of treatment. There was one severe event in the treatment arm and one in the placebo arm that led to discontinuation. Specifically, the discontinuation rates for various cognitive-related events were as follows:


    % of Patients             EQUIP (n=1,264)           CONQUER (n=2,485)
    -------------       ------------------------    -------------------------
    MedDRA Preferred               Qnexa   Qnexa               Qnexa    Qnexa
     Terms              Placebo     Low     Full    Placebo     Mid     Full
    ----------------    -------    -----   -----    -------    -----    -----
    Disturbance in
     Attention             0.4%     0.0%     1.4%      0.1%     0.0%     0.7%
    Memory Impairment      0.0%     0.0%     0.0%      0.1%     0.0%     0.5%
    Amnesia
     (forgetfulness)       0.2%     0.0%     0.6%      0.0%     0.2%     0.3%
    Aphasia (word
     finding
     difficulties)         0.0%     0.0%     0.2%      0.0%     0.0%     0.3%
    Cognitive Disorder     0.2%     0.0%     0.0%      0.0%     0.0%     0.2%
    Confusional State      0.0%     0.4%     0.2%      0.1%     0.2%     0.1%
    Bradyphrenia
     (slow thinking)       0.0%     0.0%     0.2%      0.0%     0.0%     0.0%
    Disorientation         0.0%     0.0%     0.0%      0.0%     0.0%     0.0%
    Mental Impairment      0.0%     0.0%     0.0%      0.0%     0.0%     0.0%

    Events are not additive as some patients have reported more than one event
    leading to study drug discontinuation.

Consistent with standard scientific and regulatory methodologies, these infrequent events that lead to study drug discontinuati
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 Today, ... honored 13 employees from 12 biopharmaceutical companies as ... efforts in policy advocacy and community service. ... Health Champion Awards were created by the biopharmaceutical ... excelled in their careers, but have also shown ...
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals ... focused on the development and commercialization of products for ... it will release results for the first quarter of ... closes. The Company will host a ... 6, 2015, during which Vanda management will discuss the ...
Breaking Medicine Technology:PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... update webcast/conference call after the market closes on January ... Vicente Anido, Jr., Ph.D., and Chief Financial Officer and ... 2011 guidance, give a commercial and new product pipeline ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2
(Date:4/18/2015)... 18, 2015 "I wanted to ... create a healthful juice that contained essential vitamins, ... Md. "It increases my energy, improves skin elasticity ... He developed Tapp's Juice to contain fruits, vegetables ... prevent physical and mental fatigue. It features a ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 More than ... sale now at TheCelebrityDresses.com, the #1 online store carrying ... ongoing many girls have got their perfect dresses for ... the celebrity fashion prom dresses at TheCelebrityDresses.com would be ... designed more than 2000 prom dresses inspired by the ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
(Date:4/17/2015)... 2015 Rosetta Radiology is proud to ... their list of diagnostic imaging services. This solidifies them ... the Upper East Side of Manhattan. , The new ... The addition of PET-CT, combined with Rosetta’s state of ... to work with patients through several stages of the ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2
... American Society,for Therapeutic Radiology and Oncology is pleased to ... Oriental Republic of,Uruguay, will present a special guest lecture ... 1 in Los Angeles. Dr. Vazquez, who,is a radiation ... speak October 30 at 9:00 a.m. at the Los ...
... but not all , WEDNESDAY, Oct. 17 (HealthDay News) -- ... pain. , That,s the conclusion of Israeli researchers who reviewed ... insoles to sham insoles or no treatment for back pain ... of 256 people that focused on the use of insoles ...
... Help Advance Research-, MISSION VIEJO, Calif., Oct. ... for its innovative genomic search,technology, SLIM Search(TM), Inc. ... The SLIM Search genomic search tool delivers greater ... 1.3 includes the following features: * ...
... 17 After completing its review of safety,and ... Board (DSMB) has recommended that the pivotal Phase ... Edema) Study,continue under the current protocol, without change. ... for the treatment of diabetic macular edema (DME). ...
... Oct. 17 IRIDEX,Corporation (Nasdaq: IRIX ) announced ... and Chief Executive Officer, and as a member of,the ... The Board of,Directors has appointed Theodore A. Boutacoff, who ... Directors, to serve as the Company,s President,and Chief Executive ...
... - For the Nine Months (to 31 August) a 46% Sales ... in EBIT to EUR34.8m (EUR6.2m) - Marked Improvement in Adjusted ... Fall in Interest Charges Since the IPO - CEO Dr. ... In the first nine months of its financial year (to ...
Cached Medicine News:Health News:President of Uruguay to Speak at ASTRO Annual Meeting 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 2Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 3Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 5
... cool-running, energy efficient LEDs (Light Emitting Diodes) ... see without affecting the darkened refracting environment. ... free so you'll never need to change ... a limited lifetime warranty, the best in ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: